Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LarreaRx is a biotechnology company focused on developing and commercializing therapeutic products derived from the Larrea tridentata (creosote bush) plant. The company utilizes a proprietary extraction process to isolate Nordihydroguaiaretic acid (NDGA) and other lignans known for their potent antiviral and anti-inflammatory properties. LarreaRx offers a range of over-the-counter (OTC) topical and oral formulations designed to manage viral outbreaks such as herpes simplex and shingles, as well as chronic skin conditions like psoriasis. Their business model combines direct-to-consumer sales with ongoing research into the broad-spectrum applications of Larrea-based compounds in modern medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LarreaRx.